Aug 14 (Reuters) - Critical Outcome Technologies Inc
* Critical Outcome Technologies completes phase 1 dose escalation portion of COTI-2 trial in gynecological malignancies
* Has initiated an expansion arm of its phase 1 study in patients with head and neck squamous cell carcinoma
* Company expects top-line data from head and neck squamous cell carcinoma expansion arm in 2018 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.